425 related articles for article (PubMed ID: 10884347)
1. The C-terminal regulatory domain of p53 contains a functional docking site for cyclin A.
Luciani MG; Hutchins JR; Zheleva D; Hupp TR
J Mol Biol; 2000 Jul; 300(3):503-18. PubMed ID: 10884347
[TBL] [Abstract][Full Text] [Related]
2. Activation of the DNA-binding ability of latent p53 protein by protein kinase C is abolished by protein kinase CK2.
Pospísilová S; Brázda V; Kucharíková K; Luciani MG; Hupp TR; Skládal P; Palecek E; Vojtesek B
Biochem J; 2004 Mar; 378(Pt 3):939-47. PubMed ID: 14640983
[TBL] [Abstract][Full Text] [Related]
3. Characterization of p21Cip1/Waf1 peptide domains required for cyclin E/Cdk2 and PCNA interaction.
Chen IT; Akamatsu M; Smith ML; Lung FD; Duba D; Roller PP; Fornace AJ; O'Connor PM
Oncogene; 1996 Feb; 12(3):595-607. PubMed ID: 8637717
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of cyclin A/Cdk2 phosphorylation impairs B-Myb transactivation function without affecting interactions with DNA or the CBP coactivator.
Bessa M; Saville MK; Watson RJ
Oncogene; 2001 Jun; 20(26):3376-86. PubMed ID: 11423988
[TBL] [Abstract][Full Text] [Related]
5. Cdk2 kinase phosphorylates serine 315 of human p53 in vitro.
Price BD; Hughes-Davies L; Park SJ
Oncogene; 1995 Jul; 11(1):73-80. PubMed ID: 7624134
[TBL] [Abstract][Full Text] [Related]
6. The cell-cycle regulated transcription factor B-Myb is phosphorylated by cyclin A/Cdk2 at sites that enhance its transactivation properties.
Saville MK; Watson RJ
Oncogene; 1998 Nov; 17(21):2679-89. PubMed ID: 9840932
[TBL] [Abstract][Full Text] [Related]
7. p21 contains independent binding sites for cyclin and cdk2: both sites are required to inhibit cdk2 kinase activity.
Fotedar R; Fitzgerald P; Rousselle T; Cannella D; Dorée M; Messier H; Fotedar A
Oncogene; 1996 May; 12(10):2155-64. PubMed ID: 8668341
[TBL] [Abstract][Full Text] [Related]
8. Reduction of Cdc25A contributes to cyclin E1-Cdk2 inhibition at senescence in human mammary epithelial cells.
Sandhu C; Donovan J; Bhattacharya N; Stampfer M; Worland P; Slingerland J
Oncogene; 2000 Nov; 19(47):5314-23. PubMed ID: 11103932
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule.
Fåhraeus R; Laín S; Ball KL; Lane DP
Oncogene; 1998 Feb; 16(5):587-96. PubMed ID: 9482104
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B virus-X protein upregulates the expression of p21waf1/cip1 and prolongs G1-->S transition via a p53-independent pathway in human hepatoma cells.
Park US; Park SK; Lee YI; Park JG; Lee YI
Oncogene; 2000 Jul; 19(30):3384-94. PubMed ID: 10918595
[TBL] [Abstract][Full Text] [Related]
11. Identification of cdk2 binding sites on the p27Kip1 cyclin-dependent kinase inhibitor.
Kwon TK; Nordin AA
Oncogene; 1998 Feb; 16(6):755-62. PubMed ID: 9488039
[TBL] [Abstract][Full Text] [Related]
12. Requirements for p53 and the ATM gene product in the regulation of G1/S and S phase checkpoints.
Xie G; Habbersett RC; Jia Y; Peterson SR; Lehnert BE; Bradbury EM; D'Anna JA
Oncogene; 1998 Feb; 16(6):721-36. PubMed ID: 9488036
[TBL] [Abstract][Full Text] [Related]
13. Cyclin E-cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the thymidylate synthase inhibitor Tomudex.
Yin MB; Guo B; Panadero A; Frank C; Wrzosek C; Slocum HK; Rustum YM
Exp Cell Res; 1999 Feb; 247(1):189-99. PubMed ID: 10047461
[TBL] [Abstract][Full Text] [Related]
14. The development of a CDK2-docking site peptide that inhibits p53 and sensitizes cells to death.
Ferguson M; Luciani MG; Finlan L; Rankin EM; Ibbotson S; Fersht A; Hupp TR
Cell Cycle; 2004 Jan; 3(1):80-9. PubMed ID: 14657672
[TBL] [Abstract][Full Text] [Related]
15. Analysis of beta3-endonexin mutants for their ability to interact with cyclin A.
Ohtoshi A; Otoshi H
Mol Genet Genomics; 2001 Dec; 266(4):664-71. PubMed ID: 11810239
[TBL] [Abstract][Full Text] [Related]
16. The cdk2 binding domain of p27Kip correlates with the inhibition of the kinase activity of cdk2/cyclin complexes.
Kwon TK; Buchholz MA; Nordin AA
Biochem Biophys Res Commun; 1996 Mar; 220(3):703-9. PubMed ID: 8607829
[TBL] [Abstract][Full Text] [Related]
17. Flavopiridol, a cyclin-dependent kinase inhibitor, prevents spindle inhibitor-induced endoreduplication in human cancer cells.
Motwani M; Li X; Schwartz GK
Clin Cancer Res; 2000 Mar; 6(3):924-32. PubMed ID: 10741717
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylation of mammalian CDC6 by cyclin A/CDK2 regulates its subcellular localization.
Petersen BO; Lukas J; Sørensen CS; Bartek J; Helin K
EMBO J; 1999 Jan; 18(2):396-410. PubMed ID: 9889196
[TBL] [Abstract][Full Text] [Related]
19. The cell cycle inhibitor p21CIP is phosphorylated by cyclin A-CDK2 complexes.
Jaumot M; Estañol JM; Casanovas O; Graña X; Agell N; Bachs O
Biochem Biophys Res Commun; 1997 Dec; 241(2):434-8. PubMed ID: 9425288
[TBL] [Abstract][Full Text] [Related]
20. Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53.
Rao S; Lowe M; Herliczek TW; Keyomarsi K
Oncogene; 1998 Nov; 17(18):2393-402. PubMed ID: 9811471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
